Investigación / Grupos de investigación

Grupo  27

Farmacia Hospitalaria y Farmacogenómica

Publicaciones (387)

  • Amor-García, MA; Chamorro-de-Vega, E; Rodríguez-González, CG; Iglesias-Peinado, I; Moreno-Díaz, R.

    Effects of a Pharmacist-Designed Clinical Decision Support System on Antimicrobial Stewardship

    Applied Clinical Informatics. 2024; 15(04): 679-688 Nº de citas: 1 [doi:10.1055/a-2341-8823]

  • Somoza-Fernández, B; Escudero-Vilaplana, V; Collado-Borrell, R; Perez-Ramírez, S; Villanueva-Bueno, C; Montero-Antón, MD; Herranz-Alonso, A; Sanjurjo-Saez, M.

    Severe neutropenia probably caused by enzalutamide and abiraterone in a prostate cancer patient

    JOURNAL OF ONCOLOGY PHARMACY PRACTICE. 2024; 30(7): 1268-1273 [doi:10.1177/10781552241264530]

  • Costas, DG; Ribed, A; Gimenez-Manzorro, A; Garutti, I; Sanz, FJ; Taladriz-Sender, I; Herrero, S; Rioja, Y; Carrillo, A; Herranz, A; Sanjurjo-Saez, M.

    Cost-effectiveness of preoperative pharmaceutical care consultations: a 5-year analysis

    EUROPEAN JOURNAL OF HOSPITAL PHARMACY. 2024; 32(3): [doi:10.1136/ejhpharm-2024-004222]

  • Escudero-Vilaplana V; Guisado-Gil AB; Santos-Ramos B; Herranz A.

    Development and consensus of a dashboard model to evaluate research activity in Spanish Hospital Pharmacy Services.

    FARMACIA HOSPITALARIA. 2024; 48 Suppl 1: [doi:10.1016/j.farma.2023.12.007]

  • Escudero-Vilaplana, V; Guisado-Gil, AB; Santos-Ramos, B; Herranz, A.

    Development and consensus of a dashboard model to evaluate research activity in Spanish Hospital Pharmacy Services

    FARMACIA HOSPITALARIA. 2024; 48: 28-34 [doi:10.1016/j.farma.2024.03.006]

  • Gómez-Costas D; Romero-Jiménez RM; Lobato-Matilla ME; Culebras R; González JA; Herrero-Bermejo S; Herranz-Alonso AM; Sanjurjo-Saez M.

    Detection and reduction of errors in parenteral nutrition compounding through gravimetric and product control.

    FARMACIA HOSPITALARIA. 2024; 48(3): 116-121 [doi:10.1016/j.farma.2023.11.007]

  • de Lorenzo-Pinto, A; Redondo-Galán, C; García-González, X; Fernández-Alvarez, C; Andueza-Lillo, J; Sanjurjo-Sáez, M.

    Presence of metallic components in transdermal drug delivery systems and risk of skin burns

    FARMACIA HOSPITALARIA. 2024; 48(3): 129-132 [doi:10.1016/j.farma.2024.02.010]

  • Gómez-Costas, D; Romero-Jiménez, RM; Lobato-Matilla, ME; Culebras, R; González, JA; Herrero-Bermejo, S; Herranz-Alonso, AM; Sanjurjo, M.

    Detection and reduction of errors in parenteral nutrition compounding through gravimetric and product control

    FARMACIA HOSPITALARIA. 2024; 48(3): 116-121 [doi:10.1016/j.farma.2024.02.014]

  • de Lorenzo-Pinto A; Redondo-Galán C; García-González X; Fernández-Álvarez C; Andueza-Lillo J; Sanjurjo-Sáez M.

    Presence of metallic components in transdermal drug delivery systems and risk of skin burns.

    FARMACIA HOSPITALARIA. 2024; 48(3): 129-132 [doi:10.1016/j.farma.2023.11.003]

  • Salvador-Martín S; Rubbini G; Vellosillo P; Zapata-Cobo P; Velasco M; Palomino LM; Clemente S; Segarra O; Moreno-Álvarez A; Fernández-Lorenzo A; Pérez-Moneo B; Montraveta M; Sánchez C; Tolín M; Loverdos I; Fobelo MJ; Navas-López VM; Magallares L; García-Romero R; Torres-Peral R; Rodríguez A; Bossacoma F; Merino-Bohórquez V; Salcedo E; Álvarez R; Dopazo A; Sanjurjo-Sáez M; López-Fernández LA.

    Blood gene expression biomarkers of response to anti-TNF drugs in pediatric inflammatory bowel diseases before initiation of treatment.

    BIOMEDICINE & PHARMACOTHERAPY. 2024; 173: 116299-116299 Nº de citas: 2 [doi:10.1016/j.biopha.2024.116299]

  • Clemente-Bautista, S; Trocóniz, IF; Segarra-Cantón, O; Salvador-Marín, S; Parramón-Teixidó, CJ; Alvarez-Beltrán, M; López-Fernández, LA; Colom, H; Cabañas-Poy, MJ; Gorgas-Torner, MQ; Miarons, M.

    The Effect of Polymorphisms and Other Biomarkers on Infliximab Exposure in Paediatric Inflammatory Bowel Disease: Development of a Population Pharmacokinetic Model

    PEDIATRIC DRUGS. 2024; 26(3): 331-346 Nº de citas: 2 [doi:10.1007/s40272-024-00621-1]

  • Melero, R; Torroba-Sanz, B; Goicoechea, M; Sousa-Casasnovas, I; Barrio, J; García-Prieto, A; Rodriguez-Benitez, P; García-González, X; Sanjurjo-Sáez, M.

    Treatment with Rasburicase in Hospitalized Patients with Cardiorenal Syndrome: Old Treatment, New Scenario

    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. 2024; 25(6): [doi:10.3390/ijms25063329]

  • Morillo Verdugo R; Vicente Escrig E; Murillo Izquierdo M; Ibarra Barrueta O; Taberner Bonastre P; Fernández-Llamazares CM.

    Analisis de la evolución de la atención farmacéutica al paciente externo en los servicios de farmacia hospitalaria en España tras la puesta en marcha y desarrollo de la iniciativa MAPEX.

    Journal Of Healthcare Quality Research. 2024; 39(2): 65-79 Nº de citas: 2 [doi:10.1016/j.jhqr.2023.11.002]

  • Vicente-Escrig E; Bonastre PT; Barrueta OI; Izquierdo MM; Fernández-Llamazares CM; Morillo-Verdugo R.

    [Translated article] Analysis 2016-2021 of the development of the MAPEX outpatient pharmaceutical care Project by Regions in Spain.

    FARMACIA HOSPITALARIA. 2024; 48(2): 64-69 Nº de citas: 3 [doi:10.1016/j.farma.2023.11.001]

  • Vicente-Escrig E; Taberner Bonastre P; Ibarra Barrueta O; Murillo Izquierdo M; Fernández-Llamazares CM; Morillo-Verdugo R.

    Analysis 2016-2021 of the development of the MAPEX outpatient pharmaceutical care Project by regions in Spain.

    FARMACIA HOSPITALARIA. 2024; 48(2): 64-69 [doi:10.1016/j.farma.2023.08.007]

  • Jiménez, RMR; Pinto, PH; Domínguez, MC; Mata, SA; Bellmunt, A; Prades, M; Arumi, D; Hernández-Martín, I; Herrera-Lasso, V; Llevat, N; Juste, AD; Laserna, FJR.

    Cost-Effectiveness Analysis of Abrocitinib Compared with Other Systemic Treatments for Severe Atopic Dermatitis in Spain

    Pharmacoeconomics-Open. 2024; : Nº de citas: 4 [doi:10.1007/s41669-023-00459-2]

  • González, MM; Sanz-Pastor, AG; Gómez, RA; Torrecilla, NB; Moreno, DM; Fernández, LG; Rivas, AM; Guerra, AL; Alvarez, R; Arranz, JA; Rodas, IM; Escudero, V; Sanjurjo, M; Vallejo, JM; Martín, M; Albarrán, OG.

    Endocrine Adverse Events Related To Immune Checkpoint Inhibitor Treatment: Relationship Between Antibodies and Severity of Thyroid Dysfunction

    Endocrine Metabolic & Immune Disorders-Drug Targets. 2024; 24(14): 1628-1639 Nº de citas: 1 [doi:10.2174/0118715303280679240206100137]

  • Parra, AP; Ramos, N; Perurena-Prieto, J; Manrique-Rodríguez, S; Climente, M; Quintanilla, LG; Escolano, A; Miarons, M.

    Pharmacokinetics of eculizumab in adult and pediatric patients with atypical hemolyticuremic syndrome and C3 glomerulopathy

    FARMACIA HOSPITALARIA. 2024; 48(1): 16-22 [doi:10.1016/j.farma.2023.07.009]